WEDNESDAY, SEPTEMBER 28, 2016

GeoVax presents on HIV during Washington forum

GeoVax Labs, Inc., an Atlanta-based HIV vaccine developer, announced on Tuesday that its chief scientific officer presented information this week on HIV antigens and protective antibody responses during the Phacilitate Vaccine Forum 2014.

The forum, which took place on Jan. 27 in Washington, is part of the Washington BioLeaders Forum 2014. GeoVax's Harriet Robinson spoke during a roundtable on emerging technologies and scientific approaches related to vaccines. She presented characteristics distinguishing neutralizing and protective non-neutralizing HIV antibodies.

"The concept of protective non-neutralizing antibody is important for HIV vaccines," Robinson said. "In contrast to neutralizing antibody, that vaccines have failed to elicit, protective non-neutralizing antibody can be elicited by vaccines, and may be particularly effectively elicited by vaccines that display the HIV envelope glycoprotein on virus-like particles -- such as those expressed by the GeoVax GOVX-B11 HIV vaccine."

Robinson also discussed immunogen design that elicits protective non-neutralizing antibodies and highlighted the promise of non-neutralizing antibodies for preventing HIV.

An estimated 500 to 600 people attended the event, including executives from pharma and biotech, regulators, public and private sector investors, payers, analysts and non-governmental organizations.

GeoVax's two component HIV vaccine candidate is compromised of a recombinant DNA and recombinant modified vaccinia Ankara. The vaccine is meant to stimulate both anti-HIV T cell immune responses and anti-HIV antibody responses.